SE0100902D0 - Compounds - Google Patents

Compounds

Info

Publication number
SE0100902D0
SE0100902D0 SE0100902A SE0100902A SE0100902D0 SE 0100902 D0 SE0100902 D0 SE 0100902D0 SE 0100902 A SE0100902 A SE 0100902A SE 0100902 A SE0100902 A SE 0100902A SE 0100902 D0 SE0100902 D0 SE 0100902D0
Authority
SE
Sweden
Prior art keywords
compounds
inhibitors
mmp12
useful
formula
Prior art date
Application number
SE0100902A
Other languages
English (en)
Swedish (sv)
Inventor
Anders Eriksson
Matti Lepistoe
Michael Lundkvist
Af Rosenschoeld Magnus Munck
Pavol Zlatoidsky
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Priority to SE0100902A priority Critical patent/SE0100902D0/xx
Publication of SE0100902D0 publication Critical patent/SE0100902D0/xx
Priority to AT02704037T priority patent/ATE484496T1/de
Priority to CNA028100417A priority patent/CN1509275A/zh
Priority to DK02704031T priority patent/DK1370556T3/da
Priority to CZ20032500A priority patent/CZ20032500A3/cs
Priority to KR10-2003-7011989A priority patent/KR20030082990A/ko
Priority to EEP200300451A priority patent/EE05364B1/xx
Priority to IL15765202A priority patent/IL157652A0/xx
Priority to MXPA03008181A priority patent/MXPA03008181A/es
Priority to MXPA03008177A priority patent/MXPA03008177A/es
Priority to AT06008158T priority patent/ATE493406T1/de
Priority to KR1020087017665A priority patent/KR100879905B1/ko
Priority to CA2440473A priority patent/CA2440473C/en
Priority to NZ528107A priority patent/NZ528107A/en
Priority to JP2002573759A priority patent/JP2004527511A/ja
Priority to SK1096-2003A priority patent/SK287766B6/sk
Priority to DE60213216T priority patent/DE60213216T2/de
Priority to EP02704037A priority patent/EP1370537B1/en
Priority to CN2006101061525A priority patent/CN1962641B/zh
Priority to KR1020037011987A priority patent/KR100886315B1/ko
Priority to PL02365099A priority patent/PL365099A1/xx
Priority to RU2003127735/04A priority patent/RU2293729C2/ru
Priority to SK1095-2003A priority patent/SK10952003A3/sk
Priority to PCT/SE2002/000478 priority patent/WO2002074751A1/en
Priority to EP02704031A priority patent/EP1370556B1/en
Priority to US10/471,900 priority patent/US7427631B2/en
Priority to HU0400206A priority patent/HUP0400206A3/hu
Priority to PCT/SE2002/000472 priority patent/WO2002074767A1/en
Priority to IL15765602A priority patent/IL157656A0/xx
Priority to CZ20032497A priority patent/CZ20032497A3/cs
Priority to HK04102796.8A priority patent/HK1059932B/en
Priority to CA002440631A priority patent/CA2440631A1/en
Priority to MXPA03008180A priority patent/MXPA03008180A/es
Priority to EP02704034A priority patent/EP1370536A1/en
Priority to NZ528106A priority patent/NZ528106A/en
Priority to EEP200300449A priority patent/EE200300449A/xx
Priority to IL15757002A priority patent/IL157570A0/xx
Priority to EEP200300445A priority patent/EE05431B1/xx
Priority to BR0207983-6A priority patent/BR0207983A/pt
Priority to UA2003098171A priority patent/UA78502C2/uk
Priority to EEP200300439A priority patent/EE200300439A/xx
Priority to CZ20032502A priority patent/CZ20032502A3/cs
Priority to MYPI20020904A priority patent/MY136141A/en
Priority to RU2003127732/04A priority patent/RU2003127732A/ru
Priority to JP2002573757A priority patent/JP2004523581A/ja
Priority to MXPA03008191A priority patent/MXPA03008191A/es
Priority to DE60238794T priority patent/DE60238794D1/de
Priority to JP2002573776A priority patent/JP2004527515A/ja
Priority to KR10-2003-7011981A priority patent/KR20030082986A/ko
Priority to SK1092-2003A priority patent/SK287834B6/sk
Priority to US10/471,810 priority patent/US7368465B2/en
Priority to HU0400327A priority patent/HUP0400327A3/hu
Priority to AU2002237632A priority patent/AU2002237632B2/en
Priority to CNB028097882A priority patent/CN1304377C/zh
Priority to SK1093-2003A priority patent/SK10932003A3/sk
Priority to CZ20032499A priority patent/CZ20032499A3/cs
Priority to US10/471,808 priority patent/US20040147573A1/en
Priority to BR0207984-4A priority patent/BR0207984A/pt
Priority to CA2440630A priority patent/CA2440630C/en
Priority to UA2003098168A priority patent/UA77408C2/uk
Priority to US10/471,500 priority patent/US20040106659A1/en
Priority to PL02364707A priority patent/PL364707A1/xx
Priority to AT02704031T priority patent/ATE333454T1/de
Priority to AU2002237626A priority patent/AU2002237626B2/en
Priority to EP02704032A priority patent/EP1370534A1/en
Priority to PCT/SE2002/000475 priority patent/WO2002074750A1/en
Priority to HK04102888.7A priority patent/HK1060121B/en
Priority to MYPI20020910A priority patent/MY136789A/en
Priority to ES02704031T priority patent/ES2267986T3/es
Priority to ES02704037T priority patent/ES2352246T3/es
Priority to ES06008158T priority patent/ES2357138T3/es
Priority to HU0400202A priority patent/HUP0400202A3/hu
Priority to RU2003127734/04A priority patent/RU2288228C2/ru
Priority to HU0400194A priority patent/HUP0400194A3/hu
Priority to SI200230386T priority patent/SI1370556T1/sl
Priority to UA2003098170A priority patent/UA77667C2/uk
Priority to PL02364714A priority patent/PL364714A1/xx
Priority to IL15765702A priority patent/IL157657A0/xx
Priority to CNA200910147512XA priority patent/CN101602731A/zh
Priority to NZ528140A priority patent/NZ528140A/en
Priority to CNB02809915XA priority patent/CN100526307C/zh
Priority to BR0208104-0A priority patent/BR0208104A/pt
Priority to JP2002573760A priority patent/JP4390457B2/ja
Priority to EP06008158A priority patent/EP1676846B1/en
Priority to PCT/SE2002/000473 priority patent/WO2002074748A1/en
Priority to KR10-2003-7011982A priority patent/KR20030082987A/ko
Priority to RU2003127733/04A priority patent/RU2285695C2/ru
Priority to BR0208105-9A priority patent/BR0208105A/pt
Priority to PT02704031T priority patent/PT1370556E/pt
Priority to DE60237965T priority patent/DE60237965D1/de
Priority to CA002440632A priority patent/CA2440632A1/en
Priority to PL364706A priority patent/PL205315B1/pl
Priority to CNB02810093XA priority patent/CN1269804C/zh
Priority to ARP020100944A priority patent/AR035443A1/es
Priority to ARP020100943A priority patent/AR035695A1/es
Priority to ZA200306732A priority patent/ZA200306732B/en
Priority to ZA200306731A priority patent/ZA200306731B/en
Priority to IL157656A priority patent/IL157656A/en
Priority to IL157652A priority patent/IL157652A/en
Priority to ZA200306734A priority patent/ZA200306734B/en
Priority to ZA200306737A priority patent/ZA200306737B/en
Priority to IS6942A priority patent/IS6942A/is
Priority to IS6943A priority patent/IS6943A/is
Priority to IS6946A priority patent/IS6946A/is
Priority to IS6944A priority patent/IS6944A/is
Priority to NO20034025A priority patent/NO20034025L/no
Priority to NO20034042A priority patent/NO326087B1/no
Priority to NO20034045A priority patent/NO327114B1/no
Priority to NO20034044A priority patent/NO20034044L/no
Priority to HK06112181.8A priority patent/HK1091492B/en
Priority to CY20061101477T priority patent/CY1107525T1/el
Priority to US11/928,040 priority patent/US7625934B2/en
Priority to US12/114,901 priority patent/US7666892B2/en
Priority to US12/115,785 priority patent/US7754750B2/en
Priority to JP2009256358A priority patent/JP5140058B2/ja
Priority to US12/693,852 priority patent/US8153673B2/en
Priority to US12/830,763 priority patent/US20110003853A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/72—Two oxygen atoms, e.g. hydantoin
    • C07D233/76—Two oxygen atoms, e.g. hydantoin with substituted hydrocarbon radicals attached to the third ring carbon atom
    • C07D233/78—Radicals substituted by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/72—Two oxygen atoms, e.g. hydantoin
    • C07D233/76—Two oxygen atoms, e.g. hydantoin with substituted hydrocarbon radicals attached to the third ring carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Otolaryngology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
SE0100902A 2001-03-15 2001-03-15 Compounds SE0100902D0 (sv)

Priority Applications (117)

Application Number Priority Date Filing Date Title
SE0100902A SE0100902D0 (sv) 2001-03-15 2001-03-15 Compounds
AT02704037T ATE484496T1 (de) 2001-03-15 2002-03-13 Metalloproteinaseinhibitoren
CNA028100417A CN1509275A (zh) 2001-03-15 2002-03-13 金属蛋白酶抑制剂
DK02704031T DK1370556T3 (da) 2001-03-15 2002-03-13 Metalloproteinaseinhibitorer
CZ20032500A CZ20032500A3 (cs) 2001-03-15 2002-03-13 Inhibitory metalloproteinasy
KR10-2003-7011989A KR20030082990A (ko) 2001-03-15 2002-03-13 메탈로프로테이나제 억제제
EEP200300451A EE05364B1 (et) 2001-03-15 2002-03-13 Metalloproteinaasi inhibiitorid
IL15765202A IL157652A0 (en) 2001-03-15 2002-03-13 Metalloproteinase inhibitors
MXPA03008181A MXPA03008181A (es) 2001-03-15 2002-03-13 Inhibidores de metaloproteinasa.
MXPA03008177A MXPA03008177A (es) 2001-03-15 2002-03-13 Inhibidores de metaloproteinasa..
AT06008158T ATE493406T1 (de) 2001-03-15 2002-03-13 Hydantoinderivate als mmp-inhibitoren
KR1020087017665A KR100879905B1 (ko) 2001-03-15 2002-03-13 메탈로프로테이나제 억제제
CA2440473A CA2440473C (en) 2001-03-15 2002-03-13 Metalloproteinase inhibitors
NZ528107A NZ528107A (en) 2001-03-15 2002-03-13 Metalloproteinase inhibitors
JP2002573759A JP2004527511A (ja) 2001-03-15 2002-03-13 メタロプロテイナーゼ阻害剤
SK1096-2003A SK287766B6 (sk) 2001-03-15 2002-03-13 Metaloproteinázové inhibítory
DE60213216T DE60213216T2 (de) 2001-03-15 2002-03-13 Metalloproteinaseinhibitoren
EP02704037A EP1370537B1 (en) 2001-03-15 2002-03-13 Metalloproteinase inhibitors
CN2006101061525A CN1962641B (zh) 2001-03-15 2002-03-13 金属蛋白酶抑制剂
KR1020037011987A KR100886315B1 (ko) 2001-03-15 2002-03-13 메탈로프로테이나제 억제제
PL02365099A PL365099A1 (en) 2001-03-15 2002-03-13 Metalloproteinase inhibitors
RU2003127735/04A RU2293729C2 (ru) 2001-03-15 2002-03-13 Ингибиторы металлопротеиназ, их применение и фармацевтические композиции на их основе
SK1095-2003A SK10952003A3 (sk) 2001-03-15 2002-03-13 Metaloproteinázové inhibítory
PCT/SE2002/000478 WO2002074751A1 (en) 2001-03-15 2002-03-13 Metalloproteinase inhibitors
EP02704031A EP1370556B1 (en) 2001-03-15 2002-03-13 Metalloproteinase inhibitors
US10/471,900 US7427631B2 (en) 2001-03-15 2002-03-13 Metalloproteinase inhibitors
HU0400206A HUP0400206A3 (en) 2001-03-15 2002-03-13 Imidazolidindion derivatives having metalloproteinase inhibitor effect a their use for preparation of pharmaceutical compositions and pharmaceutical compositions containing them
PCT/SE2002/000472 WO2002074767A1 (en) 2001-03-15 2002-03-13 Metalloproteinase inhibitors
IL15765602A IL157656A0 (en) 2001-03-15 2002-03-13 Metalloproteinase inhibitors
CZ20032497A CZ20032497A3 (cs) 2001-03-15 2002-03-13 Inhibitory metalloproteinasy
HK04102796.8A HK1059932B (en) 2001-03-15 2002-03-13 Metalloproteinase inhibitors
CA002440631A CA2440631A1 (en) 2001-03-15 2002-03-13 Metalloproteinase inhibitors
MXPA03008180A MXPA03008180A (es) 2001-03-15 2002-03-13 Inhibidores de metaloproteinasa.
EP02704034A EP1370536A1 (en) 2001-03-15 2002-03-13 Metalloproteinase inhibitors
NZ528106A NZ528106A (en) 2001-03-15 2002-03-13 Metalloproteinase inhibitors
EEP200300449A EE200300449A (et) 2001-03-15 2002-03-13 Metalloproteinaasi inhibiitorid
IL15757002A IL157570A0 (en) 2001-03-15 2002-03-13 Metalloproteinase inhibitors
EEP200300445A EE05431B1 (et) 2001-03-15 2002-03-13 Metalloproteinaasi inhibiitorid
BR0207983-6A BR0207983A (pt) 2001-03-15 2002-03-13 Inibidores de metaloproteinase
UA2003098171A UA78502C2 (en) 2001-03-15 2002-03-13 Metalloproteinase inhibitors, use thereof, and pharmaceutical composition based thereon
EEP200300439A EE200300439A (et) 2001-03-15 2002-03-13 Metalloproteinaasi inhibiitorid
CZ20032502A CZ20032502A3 (cs) 2001-03-15 2002-03-13 Inhibitory metalloproteinasy
MYPI20020904A MY136141A (en) 2001-03-15 2002-03-13 Novel hydantoin derivatives and pharmaceutical compositions useful as metalloproteinase inhibitors
RU2003127732/04A RU2003127732A (ru) 2001-03-15 2002-03-13 Ингибиторы металлопротеиназ
JP2002573757A JP2004523581A (ja) 2001-03-15 2002-03-13 メタロプロテイナーゼ阻害剤
MXPA03008191A MXPA03008191A (es) 2001-03-15 2002-03-13 Inhibidores de metaloproteinasa.
DE60238794T DE60238794D1 (de) 2001-03-15 2002-03-13 Hydantoinderivate als MMP-Inhibitoren
JP2002573776A JP2004527515A (ja) 2001-03-15 2002-03-13 メタロプロテイナーゼ阻害剤
KR10-2003-7011981A KR20030082986A (ko) 2001-03-15 2002-03-13 메탈로프로테이나제 억제제
SK1092-2003A SK287834B6 (sk) 2001-03-15 2002-03-13 Metalloproteinase inhibitors
US10/471,810 US7368465B2 (en) 2001-03-15 2002-03-13 Metalloproteinase inhibitors
HU0400327A HUP0400327A3 (en) 2001-03-15 2002-03-13 Azole derivatives having metalloproteinase inhibitor effect pharmaceutical compositions containing them and their use
AU2002237632A AU2002237632B2 (en) 2001-03-15 2002-03-13 Metalloproteinase inhibitors
CNB028097882A CN1304377C (zh) 2001-03-15 2002-03-13 金属蛋白酶抑制剂
SK1093-2003A SK10932003A3 (sk) 2001-03-15 2002-03-13 Metaloproteinázové inhibítory
CZ20032499A CZ20032499A3 (cs) 2001-03-15 2002-03-13 Inhibitory metaloproteinasy
US10/471,808 US20040147573A1 (en) 2001-03-15 2002-03-13 Metalloproteinase inhibitors
BR0207984-4A BR0207984A (pt) 2001-03-15 2002-03-13 Inibidores de metaloproteinase
CA2440630A CA2440630C (en) 2001-03-15 2002-03-13 Metalloproteinase inhibitors
UA2003098168A UA77408C2 (en) 2001-03-15 2002-03-13 Metalloproteinase inhibitors, pharmaceutical composition on its base, and use thereof
US10/471,500 US20040106659A1 (en) 2001-03-15 2002-03-13 Metalloproteinase inhibitors
PL02364707A PL364707A1 (en) 2001-03-15 2002-03-13 Metalloproteinase inhibitors
AT02704031T ATE333454T1 (de) 2001-03-15 2002-03-13 Metalloproteinaseinhibitoren
AU2002237626A AU2002237626B2 (en) 2001-03-15 2002-03-13 Metalloproteinase inhibitors
EP02704032A EP1370534A1 (en) 2001-03-15 2002-03-13 Metalloproteinase inhibitors
PCT/SE2002/000475 WO2002074750A1 (en) 2001-03-15 2002-03-13 Metalloproteinase inhibitors
HK04102888.7A HK1060121B (en) 2001-03-15 2002-03-13 Metalloproteinase inhibitors
MYPI20020910A MY136789A (en) 2001-03-15 2002-03-13 Metalloproteinase inhibitors
ES02704031T ES2267986T3 (es) 2001-03-15 2002-03-13 Inhibidores de metaloproteinasas.
ES02704037T ES2352246T3 (es) 2001-03-15 2002-03-13 Inhibidores de metaloproteinasas.
ES06008158T ES2357138T3 (es) 2001-03-15 2002-03-13 Derivados de hidantoína como inhibidores de mmp.
HU0400202A HUP0400202A3 (en) 2001-03-15 2002-03-13 Imidazolidindion derivatives having metalloproteinase inhibitor effect, their use and pharmaceutical compositions containing them
RU2003127734/04A RU2288228C2 (ru) 2001-03-15 2002-03-13 Ингибиторы металлопротеиназ, их применение и фармацевтические композиции на их основе
HU0400194A HUP0400194A3 (en) 2001-03-15 2002-03-13 Imidazolidindion derivatives as metalloproteinase inhibitors, their use and pharmaceutical compositions containing them
SI200230386T SI1370556T1 (sl) 2001-03-15 2002-03-13 Metaloproteinazni inhibitorji
UA2003098170A UA77667C2 (en) 2001-03-15 2002-03-13 Metalloproteinase inhibitors, pharmaceutical composition and use thereof
PL02364714A PL364714A1 (en) 2001-03-15 2002-03-13 Metalloproteinase inhibitors
IL15765702A IL157657A0 (en) 2001-03-15 2002-03-13 Metalloproteinase inhibitors
CNA200910147512XA CN101602731A (zh) 2001-03-15 2002-03-13 金属蛋白酶抑制剂
NZ528140A NZ528140A (en) 2001-03-15 2002-03-13 Metalloproteinase inhibitors
CNB02809915XA CN100526307C (zh) 2001-03-15 2002-03-13 金属蛋白酶抑制剂
BR0208104-0A BR0208104A (pt) 2001-03-15 2002-03-13 Inibidores de metaloproteinase
JP2002573760A JP4390457B2 (ja) 2001-03-15 2002-03-13 メタロプロテイナーゼ阻害剤
EP06008158A EP1676846B1 (en) 2001-03-15 2002-03-13 Hydantoin derivatives as MMP inhibitors
PCT/SE2002/000473 WO2002074748A1 (en) 2001-03-15 2002-03-13 Metalloproteinase inhibitors
KR10-2003-7011982A KR20030082987A (ko) 2001-03-15 2002-03-13 메탈로프로테이나제 억제제
RU2003127733/04A RU2285695C2 (ru) 2001-03-15 2002-03-13 Производные имидазолидин-2,4-диона, содержащие их фармацевтические композиции и их применение
BR0208105-9A BR0208105A (pt) 2001-03-15 2002-03-13 Inibidores de metaloproteinase
PT02704031T PT1370556E (pt) 2001-03-15 2002-03-13 Inibidores de metaloproteinases
DE60237965T DE60237965D1 (en) 2001-03-15 2002-03-13 Metalloproteinaseinhibitoren
CA002440632A CA2440632A1 (en) 2001-03-15 2002-03-13 Metalloproteinase inhibitors
PL364706A PL205315B1 (pl) 2001-03-15 2002-03-13 Pochodne imidazolidynodionu, środek farmaceutyczny i zastosowanie tych pochodnych
CNB02810093XA CN1269804C (zh) 2001-03-15 2002-03-13 金属蛋白酶抑制剂
ARP020100944A AR035443A1 (es) 2001-03-15 2002-03-15 Compuestos inhibidores de metaloproteinasa, composicion farmaceutica, metodo de tratamiento, y uso de estos compuestos para la preparacion de medicamentos.
ARP020100943A AR035695A1 (es) 2001-03-15 2002-03-15 Compuestos inhibidores de metaloproteinasa, composicion farmaceutica, metodo de tratamiento, y uso de estos compuestos para la preparacion de medicamentos
ZA200306732A ZA200306732B (en) 2001-03-15 2003-08-28 Metalloproteinase inhibitors.
ZA200306731A ZA200306731B (en) 2001-03-15 2003-08-28 Metalloproteinase inhibitors.
IL157656A IL157656A (en) 2001-03-15 2003-08-28 Metalloproteinase inhibitors, pharmaceutical compositions comprising them and use thereof in the preparation of medicaments for the treatment of diseases mediated by metalloproteinase enzymes
IL157652A IL157652A (en) 2001-03-15 2003-08-28 Metalloproteinase inhibitors, compositions comprising them and uses thereof for the preparation of medicaments for treating diseases or conditions mediated by metalloproteinase enzymes
ZA200306734A ZA200306734B (en) 2001-03-15 2003-08-28 Metalloproteinase inhibitors.
ZA200306737A ZA200306737B (en) 2001-03-15 2003-08-28 Metalloproteinase inhibitors.
IS6942A IS6942A (is) 2001-03-15 2003-09-09 Málmpróteinasatálmar
IS6943A IS6943A (is) 2001-03-15 2003-09-09 Málmpróteinasatálmar
IS6946A IS6946A (is) 2001-03-15 2003-09-10 Málmpróteinasatálmar
IS6944A IS6944A (is) 2001-03-15 2003-09-10 Málmpróteinasatálmar
NO20034025A NO20034025L (no) 2001-03-15 2003-09-11 Metalloproteinaseinhibitorer
NO20034042A NO326087B1 (no) 2001-03-15 2003-09-12 Metallproteinaseinhibitorer, farmasoytiske sammensetninger inneholdende slike samt anvendelser derav
NO20034045A NO327114B1 (no) 2001-03-15 2003-09-12 Metallproteinaseinhibitorer, farmasoytiske sammensetninger som omfatter slike, og anvendelser derav.
NO20034044A NO20034044L (no) 2001-03-15 2003-09-12 Metallproteinase-inhibitorer
HK06112181.8A HK1091492B (en) 2001-03-15 2004-04-21 Hydantoin derivatives as mmp inhibitors
CY20061101477T CY1107525T1 (el) 2001-03-15 2006-10-13 Αναστολεiς μεταλλοπρωτεϊνασης
US11/928,040 US7625934B2 (en) 2001-03-15 2007-10-30 Metalloproteinase inhibitors
US12/114,901 US7666892B2 (en) 2001-03-15 2008-05-05 Metalloproteinase inhibitors
US12/115,785 US7754750B2 (en) 2001-03-15 2008-05-06 Metalloproteinase inhibitors
JP2009256358A JP5140058B2 (ja) 2001-03-15 2009-11-09 メタロプロテイナーゼ阻害剤
US12/693,852 US8153673B2 (en) 2001-03-15 2010-01-26 Metalloproteinase inhibitors
US12/830,763 US20110003853A1 (en) 2001-03-15 2010-07-06 Metalloproteinase Inhibitors

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0100902A SE0100902D0 (sv) 2001-03-15 2001-03-15 Compounds

Publications (1)

Publication Number Publication Date
SE0100902D0 true SE0100902D0 (sv) 2001-03-15

Family

ID=20283374

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0100902A SE0100902D0 (sv) 2001-03-15 2001-03-15 Compounds

Country Status (32)

Country Link
US (8) US7427631B2 (enExample)
EP (4) EP1370537B1 (enExample)
JP (4) JP4390457B2 (enExample)
KR (4) KR20030082986A (enExample)
CN (5) CN101602731A (enExample)
AR (2) AR035695A1 (enExample)
AT (3) ATE333454T1 (enExample)
AU (2) AU2002237626B2 (enExample)
BR (3) BR0208104A (enExample)
CA (3) CA2440630C (enExample)
CY (1) CY1107525T1 (enExample)
CZ (3) CZ20032499A3 (enExample)
DE (3) DE60213216T2 (enExample)
DK (1) DK1370556T3 (enExample)
EE (3) EE200300449A (enExample)
ES (3) ES2357138T3 (enExample)
HU (3) HUP0400194A3 (enExample)
IL (5) IL157652A0 (enExample)
IS (3) IS6943A (enExample)
MX (3) MXPA03008181A (enExample)
MY (2) MY136141A (enExample)
NO (3) NO20034044L (enExample)
NZ (3) NZ528107A (enExample)
PL (3) PL365099A1 (enExample)
PT (1) PT1370556E (enExample)
RU (3) RU2285695C2 (enExample)
SE (1) SE0100902D0 (enExample)
SI (1) SI1370556T1 (enExample)
SK (3) SK287766B6 (enExample)
UA (3) UA77667C2 (enExample)
WO (3) WO2002074751A1 (enExample)
ZA (4) ZA200306731B (enExample)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0100902D0 (sv) * 2001-03-15 2001-03-15 Astrazeneca Ab Compounds
SE0100903D0 (sv) * 2001-03-15 2001-03-15 Astrazeneca Ab Compounds
WO2002096426A1 (en) 2001-05-25 2002-12-05 Bristol-Myers Squibb Company Hydantion derivatives as inhibitors of matrix metalloproteinases
SE0103710D0 (sv) 2001-11-07 2001-11-07 Astrazeneca Ab Compounds
DE10221018A1 (de) * 2002-05-11 2003-11-27 Boehringer Ingelheim Pharma Verwendung von Hemmern der EGFR-vermittelten Signaltransduktion zur Behandlung von gutartiger Prostatahyperplasie (BPH)/Prostatahypertrophie
SE0202539D0 (sv) * 2002-08-27 2002-08-27 Astrazeneca Ab Compounds
SE0202693D0 (sv) * 2002-09-11 2002-09-11 Astrazeneca Ab Compounds
GB0221246D0 (en) * 2002-09-13 2002-10-23 Astrazeneca Ab Compounds
AU2003282920A1 (en) * 2002-10-04 2004-05-04 Bristol-Myers Squibb Company Hydantoin derivatives as inhibitors of matrix metalloproteinases and/or tnf-alpha converting enzyme (tace)
EP2426120A1 (en) 2003-08-18 2012-03-07 Fujifilm Finechemicals Co., Ltd. Pyridyltetrahydropyridines and pyridylpiperidines, and method of manufacturing them
WO2005090316A1 (en) * 2004-03-12 2005-09-29 Wyeth HYDANTOINS HAVING RNase MODULATORY ACTIVITY
US7648992B2 (en) * 2004-07-05 2010-01-19 Astrazeneca Ab Hydantoin derivatives for the treatment of obstructive airway diseases
SE0401762D0 (sv) * 2004-07-05 2004-07-05 Astrazeneca Ab Novel compounds
SE0401763D0 (sv) * 2004-07-05 2004-07-05 Astrazeneca Ab Compounds
WO2006029173A2 (en) * 2004-09-08 2006-03-16 Boys Town National Research Hospital Treatment of glomerular basement membrane disease involving matrix metalloproteinase-12
AU2005286728A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as mediators of stearoyl-CoA desaturase
WO2006101521A2 (en) 2004-09-20 2006-09-28 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
EP1799664A1 (en) 2004-09-20 2007-06-27 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
BRPI0515505A (pt) 2004-09-20 2008-07-29 Xenon Pharmaceuticals Inc derivados heterocìclicos e sua utilização como inibidores da estearoil-coa desaturase
CA2580845A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Pyridazine derivatives for inhibiting human stearoyl-coa-desaturase
AR051026A1 (es) * 2004-09-20 2006-12-13 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso como inhibidores de la estearoil-coa desaturasa
EP1799667B1 (en) 2004-09-20 2013-03-20 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as therapeutic agents
GB0427403D0 (en) * 2004-12-15 2005-01-19 Astrazeneca Ab Novel compounds I
SE0403085D0 (sv) * 2004-12-17 2004-12-17 Astrazeneca Ab Novel componds
SE0403086D0 (sv) * 2004-12-17 2004-12-17 Astrazeneca Ab Compounds
WO2006099598A2 (en) * 2005-03-16 2006-09-21 Sensus Metering Systems Inc. Determining a physical location of a sensor
CA2618646A1 (en) 2005-06-03 2007-11-15 Xenon Pharmaceuticals Inc. Aminothiazole derivatives as human stearoyl-coa desaturase inhibitors
CA2636929A1 (en) * 2005-12-21 2007-07-12 Decode Genetics, Ehf Biaryl nitrogen heterocycle inhibitors of lta4h for treating inflammation
PE20071241A1 (es) 2006-01-17 2008-01-14 Schering Corp Compuestos derivados de hidantoina para el tratamiento de trastornos inflamatorios
TW200800954A (en) * 2006-03-16 2008-01-01 Astrazeneca Ab Novel crystal modifications
TW200740769A (en) * 2006-03-16 2007-11-01 Astrazeneca Ab Novel process
MX2008014154A (es) * 2006-05-12 2008-11-18 Sca Hygiene Prod Ab Articulo absorbente del tipo de calzoncillos y un metodo para producir articulos absorbentes de tipo de calzoncillos.
PL2024178T3 (pl) * 2006-05-12 2013-06-28 Essity Hygiene & Health Ab Sprężysty laminat i sposób wytwarzania sprężystego laminatu
WO2008053199A1 (en) * 2006-10-30 2008-05-08 Astrazeneca Ab Combination therapy for the treatment of respiratory diseases
TW200831488A (en) 2006-11-29 2008-08-01 Astrazeneca Ab Novel compounds
GB0702456D0 (en) 2007-02-08 2007-03-21 Astrazeneca Ab New combination
WO2009007747A2 (en) * 2007-07-11 2009-01-15 Astrazeneca Ab Hydantoin derivatives used as mmp12 inhibitors
US8303561B2 (en) 2007-11-14 2012-11-06 Sca Hygiene Products Ab Method of producing an absorbent garment, and an absorbent garment produced according to the method
US20100262110A1 (en) 2007-11-14 2010-10-14 Sca Hygiene Products Ab Method of producing an absorbent garment, and an absorbent garment produced according to the method
FR2927330B1 (fr) * 2008-02-07 2010-02-19 Sanofi Aventis Derives de 5,6-bisaryl-2-pyridine-carboxamide, leur preparation et leur application en therapeutique comme antagonistes des recepteurs a l'urotensine ii
CA2722658C (en) 2008-04-28 2018-09-18 Richard L. Watson Compositions and methods for treating multiple sclerosis
FR2944524B1 (fr) * 2009-04-17 2012-11-30 Ipsen Pharma Sas Derives d'imidazolidine-2,4-dione et leur utilisation comme medicament
DK2433940T3 (en) * 2009-04-28 2015-01-12 Chugai Pharmaceutical Co Ltd Spiroimidazolonderivat
GB0913345D0 (en) 2009-07-31 2009-09-16 Astrazeneca Ab New combination 802
CN102711991B (zh) * 2009-11-06 2015-01-21 巴斯夫欧洲公司 含铁和锰的非均相催化剂和通过一氧化碳与氢气反应而制备烯烃的方法
WO2011061527A1 (en) 2009-11-17 2011-05-26 Astrazeneca Ab Combinations comprising a glucocorticoid receptor modulator for the treatment of respiratory diseases
WO2011073662A1 (en) 2009-12-17 2011-06-23 Astrazeneca Ab Combination of a benzoxazinone and a further agent for treating respiratory diseases
US20110202284A1 (en) * 2010-02-10 2011-08-18 Mcreynolds Cristopher Novel groups of biomarkers for diagnosing alzheimer's disease
RU2441069C2 (ru) * 2010-03-11 2012-01-27 Галина Ивановна Эль-Регистан Стабилизатор ферментных белков
RU2441068C2 (ru) * 2010-03-11 2012-01-27 Галина Ивановна Эль-Регистан Способ направленного изменения активности ферментных белков
RU2430371C1 (ru) * 2010-04-26 2011-09-27 Учреждение Российской академии наук Институт ядерной физики им. Г.И. Будкера Сибирского отделения РАН (ИЯФ СО РАН) Способ дифференциальной диагностики и прогноза миомы и рака эндометрия
JP5813101B2 (ja) 2010-06-04 2015-11-17 アルバニー モレキュラー リサーチ， インコーポレイテッド グリシントランスポーター−１阻害剤、その作製方法および使用方法
GB201021992D0 (en) 2010-12-23 2011-02-02 Astrazeneca Ab Compound
GB201021979D0 (en) 2010-12-23 2011-02-02 Astrazeneca Ab New compound
ES2835248T3 (es) * 2012-09-04 2021-06-22 Jiangsu Hengrui Medicine Co Derivados de imidazolina, métodos de preparación de los mismos y sus aplicaciones en medicina
MA38250B1 (fr) 2012-12-10 2017-10-31 Chugai Pharmaceutical Co Ltd Nouveau dérivés d'hydantoïne pour leurs utilisations dans le traitement de maladies, comme l'osteoporose et la thrombocytopenie
US20160287650A1 (en) * 2013-11-13 2016-10-06 Hankkija Oy A Feed Supplement and a Feed Composition Comprising Resin Acid Based Composition
WO2015100613A1 (en) * 2013-12-31 2015-07-09 Beaufour Ipsen Tianjin Pharmaceutical Co., Ltd Novel imidazolidine-2, 4-dione derivatives
EP2907512A1 (en) 2014-02-14 2015-08-19 Commissariat A L'energie Atomique Et Aux Energies Alternatives Inhibitors of MMP-12 as antiviral Agents
CN106572994B (zh) * 2014-06-09 2020-09-18 中外制药株式会社 含有乙内酰脲衍生物的药物组合物
SI3209655T1 (sl) 2014-10-24 2020-11-30 Landos Biopharma, Inc. Terapevtiki na osnovi C-podobne lantionin sintetaze 2
JO3501B1 (ar) 2014-12-22 2020-07-05 Servier Lab مشتقات 5-{(بيبرازين - 1-يل)-3-أوكسو - بروبيل}- إيميدازوليدين-2، 4 - دايون كمثبطات ل adamts لمعالجة هشاشة العظام)
RU2735600C2 (ru) * 2016-09-23 2020-11-05 Какен Фармасьютикал Ко., Лтд. Способ получения (r)-5-(3,4-дифторфенил)-5-[(3-метил-2-оксопиридин-1(2h)-ил)метил]имидазолидин-2,4-диона и промежуточное соединение для его получения
WO2021011723A1 (en) * 2019-07-18 2021-01-21 Avidence Therapeutics, Inc. Anti-osteoarthritis hydantoin compounds and related compositions and methods
KR20220100933A (ko) * 2019-11-14 2022-07-18 포시 파마슈티컬스 컴퍼니 리미티드 기질 금속단백분해효소(mmp) 억제제 및 이의 사용 방법
AU2020407645B2 (en) 2019-12-20 2022-10-06 Nimmune Biopharma, Inc. Lanthionine C-like protein 2 ligands, cells prepared therewith, and therapies using same
US12234578B2 (en) 2020-01-29 2025-02-25 Wisconsin Alumni Research Foundation Tannin composite fibers
WO2021260387A1 (en) 2020-06-26 2021-12-30 The University Of Birmingham Mmp-9 and mmp-12 inhibition for treating spinal cord injury or related injury to neurological tissue
CN115720578B (zh) * 2020-07-09 2025-06-13 深圳信立泰药业股份有限公司 并三环类衍生物、其制备方法及其在医药上的应用
CN112574193B (zh) * 2020-12-31 2022-05-17 南京医科大学 一类口服gsnor抑制剂及其药物用途

Family Cites Families (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2327890A (en) * 1940-04-17 1943-08-24 Parke Davis & Co Substituted phenoxyalkyl ethers
US2745875A (en) 1953-06-30 1956-05-15 Hoechst Ag Preparation of nu-acylamino-phenylpropane diols
US3452040A (en) * 1966-01-05 1969-06-24 American Home Prod 5,5-disubstituted hydantoins
US3529019A (en) * 1968-04-23 1970-09-15 Colgate Palmolive Co Alkylaryloxy alanines
CS152617B1 (enExample) 1970-12-29 1974-02-22
CS151744B1 (enExample) * 1971-01-19 1973-11-19
US3849574A (en) * 1971-05-24 1974-11-19 Colgate Palmolive Co Alpha-substituted-beta-arylthioalkyl amino-acids,for increasing heart rate
US4315031A (en) 1977-09-01 1982-02-09 Science Union Et Cie Thiosubstituted amino acids
GB1601310A (en) * 1978-05-23 1981-10-28 Lilly Industries Ltd Aryl hydantoins
JPS6172762A (ja) 1984-09-17 1986-04-14 Kanegafuchi Chem Ind Co Ltd 光学活性ヒダントイン類の製造法
JPS61212292A (ja) * 1985-03-19 1986-09-20 Mitsui Toatsu Chem Inc Ｄ−α−アミノ酸の製造方法
CA1325222C (en) 1985-08-23 1993-12-14 Lederle (Japan), Ltd. Process for producing 4-biphenylylacetic acid
GB8618559D0 (en) 1986-07-30 1986-09-10 Genetics Int Inc Rhodococcus bacterium
JPH0279879A (ja) 1988-09-17 1990-03-20 Canon Inc 画像形成装置
US4983771A (en) * 1989-09-18 1991-01-08 Hexcel Corporation Method for resolution of D,L-alpha-phenethylamine with D(-)mandelic acid
NL9000386A (nl) 1990-02-16 1991-09-16 Stamicarbon Werkwijze voor de bereiding van optisch aktief aminozuuramide.
DK161690D0 (da) 1990-07-05 1990-07-05 Novo Nordisk As Fremgangsmaade til fremstilling af enantiomere forbindelser
IL99957A0 (en) 1990-11-13 1992-08-18 Merck & Co Inc Piperidinylcamphorsulfonyl oxytocin antagonists and pharmaceutical compositions containing them
PH31245A (en) 1991-10-30 1998-06-18 Janssen Pharmaceutica Nv 1,3-Dihydro-2H-imidazoÄ4,5-BÜ-quinolin-2-one derivatives.
US5308853A (en) * 1991-12-20 1994-05-03 Warner-Lambert Company Substituted-5-methylidene hydantoins with AT1 receptor antagonist properties
US5246943A (en) * 1992-05-19 1993-09-21 Warner-Lambert Company Substituted 1,2,3,4-tetahydroisoquinolines with angiotensin II receptor antagonist properties
NL9201230A (nl) 1992-07-09 1994-02-01 Dsm Nv Werkwijze voor de bereiding van optisch aktief methionineamide.
EP0640594A1 (en) 1993-08-23 1995-03-01 Fujirebio Inc. Hydantoin derivative as metalloprotease inhibitor
JPH07105549A (ja) 1993-09-30 1995-04-21 Canon Inc 光学的情報記録再生方法及び光学的情報記録再生装置
AU687953B2 (en) 1993-11-16 1998-03-05 Merck & Co., Inc. Piperidinylcamphorsulfonyl oxytocin antagonists
CN1048247C (zh) 1994-01-31 2000-01-12 美国辉瑞有限公司 神经保护的苯并二氢吡喃化合物
DE69534213T2 (de) 1994-10-25 2006-01-12 Astrazeneca Ab Therapeutisch wirksame Heterocyclen
ZA96211B (en) 1995-01-12 1996-07-26 Teva Pharma Compositions containing and methods of using 1- aminoindan and derivatives thereof and process for preparing optically active 1-aminoindan derivatives
US5863949A (en) 1995-03-08 1999-01-26 Pfizer Inc Arylsulfonylamino hydroxamic acid derivatives
US6166041A (en) * 1995-10-11 2000-12-26 Euro-Celtique, S.A. 2-heteroaryl and 2-heterocyclic benzoxazoles as PDE IV inhibitors for the treatment of asthma
DE19540027A1 (de) * 1995-10-27 1997-04-30 Gruenenthal Gmbh Substituierte Imidazolidin-2,4-dion-Verbindungen als pharmazeutische Wirkstoffe
IL123431A (en) * 1995-11-22 2001-05-20 Darwin Discovery Ltd Mercaptoalkyl peptidil compounds with imidazole transducer and their use as metallic protonase matrix (MMP) compounds and / or tumor cause factor (TNF)
GB9616643D0 (en) * 1996-08-08 1996-09-25 Chiroscience Ltd Compounds
US5919790A (en) * 1996-10-11 1999-07-06 Warner-Lambert Company Hydroxamate inhibitors of interleukin-1β converting enzyme
US5804593A (en) * 1996-10-22 1998-09-08 Pharmacia & Upjohn Company α-Amino sulfonyl hydroxamic acids as matrix metalloproteinase inhibitors
IL132170A0 (en) * 1997-05-06 2001-03-19 Novo Nordisk As Novel heterocyclic compounds
PT877019E (pt) * 1997-05-09 2002-05-31 Hoechst Ag Acidos diaminocarboxilicos substituidos
AU746853B2 (en) 1997-06-21 2002-05-02 Roche Diagnostics Gmbh Barbituric acid derivatives with antimetastatic and antitumor activity
DE19726427A1 (de) 1997-06-23 1998-12-24 Boehringer Mannheim Gmbh Pyrimidin-2,4,6-trion-Derivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
KR100419353B1 (ko) 1997-07-31 2004-02-19 아보트 러보러터리즈 Ｎ-하이드록시포름아미드 유도체 및 이를 포함하는 매트릭스 메탈로프로테이나제 억제용 조성물
TW514634B (en) 1997-10-14 2002-12-21 Lilly Co Eli Process to make chiral compounds
IL135921A (en) 1997-11-12 2005-08-31 Darwin Discovery Ltd Hydroxamic and carboxylic acid derivatives having mmp and tnf inhibitory activity
SK11692000A3 (sk) 1998-02-04 2001-02-12 Novartis Ag Sulfonylaminoderiváty, ktoré inhibujú metaloproteinázy degradujúce matricu, spôsob ich prípravy a farmaceutická kompozícia, ktorá ich obsahuje
US6329418B1 (en) * 1998-04-14 2001-12-11 The Procter & Gamble Company Substituted pyrrolidine hydroxamate metalloprotease inhibitors
EP1077974A1 (en) * 1998-05-14 2001-02-28 Du Pont Pharmaceuticals Company Substituted aryl hydroxamic acids as metalloproteinase inhibitors
US7459473B2 (en) 1998-06-03 2008-12-02 Glia Med, Inc. N-linked sulfonamides of N-heterocyclic carboxylic acids or carboxylic acid isosteres
EP1087937A1 (en) 1998-06-17 2001-04-04 Du Pont Pharmaceuticals Company Cyclic hydroxamic acids as metalloproteinase inhibitors
FR2782082B3 (fr) * 1998-08-05 2000-09-22 Sanofi Sa Formes cristallines de (r)-(+)-n-[[3-[1-benzoyl-3-(3,4- dichlorophenyl)piperidin-3-yl]prop-1-yl]-4-phenylpiperidin-4 -yl]-n-methylacetamide (osanetant) et procede pour la preparation dudit compose
US6339101B1 (en) 1998-08-14 2002-01-15 Gpi Nil Holdings, Inc. N-linked sulfonamides of N-heterocyclic carboxylic acids or isosteres for vision and memory disorders
JP2000127349A (ja) * 1998-08-21 2000-05-09 Komori Corp 凹版印刷機
EP1107953A1 (en) 1998-08-29 2001-06-20 British Biotech Pharmaceuticals Limited Hydroxamic acid derivatives as proteinase inhibitors
GB9919776D0 (en) 1998-08-31 1999-10-27 Zeneca Ltd Compoujnds
EP1117616B1 (en) 1998-10-07 2003-04-23 Yazaki Corporation Sol-gel process using porous mold
EP1004578B1 (en) * 1998-11-05 2004-02-25 Pfizer Products Inc. 5-oxo-pyrrolidine-2-carboxylic acid hydroxamide derivatives
CZ20012006A3 (cs) 1998-12-18 2002-03-13 Axys Pharmaceuticals, Inc. Sloučenina a farmaceutický prostředek
AU1817700A (en) * 1998-12-31 2000-07-24 Aventis Pharmaceuticals Inc. 1-carboxymethyl-2-oxo-azepan derivatives useful as selective inhibitors of mmp-12
US6340691B1 (en) * 1999-01-27 2002-01-22 American Cyanamid Company Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase and tace inhibitors
PL349354A1 (en) 1999-01-28 2002-07-15 Chugai Pharmaceutical Co Ltd Substituted phenethylamine derivatives
US6294694B1 (en) 1999-06-04 2001-09-25 Wisconsin Alumni Research Foundation Matrix metalloproteinase inhibitors and method of using same
GB9916562D0 (en) 1999-07-14 1999-09-15 Pharmacia & Upjohn Spa 3-Arylsulfonyl-2-(substituted-methyl) propanoic acid derivatives as matrix metalloproteinase inhibitora
US20020006920A1 (en) * 1999-07-22 2002-01-17 Robinson Ralph Pelton Arylsulfonylamino hydroxamic acid derivatives
US6266453B1 (en) 1999-07-26 2001-07-24 Computerized Medical Systems, Inc. Automated image fusion/alignment system and method
EP1078923B1 (en) 1999-08-02 2006-03-08 F. Hoffmann-La Roche Ag Process for the preparation of benzothiophene derivatives
SK1812002A3 (en) 1999-08-12 2003-02-04 Pharmacia Italia Spa 3(5)-Amino-pyrazole derivatives, process for their preparation and their use as antitumor agents
JP3710964B2 (ja) 1999-08-26 2005-10-26 富士通株式会社 ディスプレイデバイスのレイアウト設計方法
SE9904044D0 (sv) 1999-11-09 1999-11-09 Astra Ab Compounds
US6525202B2 (en) 2000-07-17 2003-02-25 Wyeth Cyclic amine phenyl beta-3 adrenergic receptor agonists
AU2001278709A1 (en) 2000-08-11 2002-02-25 Kaken Pharmaceutical Co..Ltd. 2,3-diphenylpropionic acid derivatives or their salts, medicines or cell adhesion inhibitors containing the same, and their usage
US20020065219A1 (en) 2000-08-15 2002-05-30 Naidu B. Narasimhulu Water soluble thiazolyl peptide derivatives
US20020091107A1 (en) * 2000-09-08 2002-07-11 Madar David J. Oxazolidinone antibacterial agents
WO2002020515A1 (en) 2000-09-08 2002-03-14 Abbott Laboratories Oxazolidinone antibacterial agents
EP1191024A1 (en) 2000-09-22 2002-03-27 Harald Tschesche Thiadiazines and their use as inhibitors of metalloproteinases
BR0208105A (pt) 2001-03-15 2004-03-09 Astrazeneca Ab Inibidores de metaloproteinase
SE0100902D0 (sv) 2001-03-15 2001-03-15 Astrazeneca Ab Compounds
SE0100903D0 (sv) 2001-03-15 2001-03-15 Astrazeneca Ab Compounds
WO2002096426A1 (en) 2001-05-25 2002-12-05 Bristol-Myers Squibb Company Hydantion derivatives as inhibitors of matrix metalloproteinases
GB0114004D0 (en) * 2001-06-08 2001-08-01 Glaxo Group Ltd Chemical compounds
SE0103710D0 (sv) 2001-11-07 2001-11-07 Astrazeneca Ab Compounds
EP2287152B1 (en) 2002-06-05 2015-01-14 Kaneka Corporation Process for producing optically active alpha-methylcysteine derivative
SE0202539D0 (sv) 2002-08-27 2002-08-27 Astrazeneca Ab Compounds
SE0202692D0 (sv) 2002-09-11 2002-09-11 Astrazeneca Ab Compounds
SE0202693D0 (sv) 2002-09-11 2002-09-11 Astrazeneca Ab Compounds
GB0221250D0 (en) * 2002-09-13 2002-10-23 Astrazeneca Ab Compounds
GB0221246D0 (en) * 2002-09-13 2002-10-23 Astrazeneca Ab Compounds
US6890913B2 (en) * 2003-02-26 2005-05-10 Food Industry Research And Development Institute Chitosans
US20040266832A1 (en) * 2003-06-26 2004-12-30 Li Zheng J. Crystal forms of 2-(3-difluoromethyl-5-phenyl-pyrazol-1-yl)-5-methanesulfonyl pyridine
TWI220073B (en) * 2003-07-24 2004-08-01 Au Optronics Corp Method for manufacturing polysilicon film
US7648992B2 (en) * 2004-07-05 2010-01-19 Astrazeneca Ab Hydantoin derivatives for the treatment of obstructive airway diseases
SE0401762D0 (sv) 2004-07-05 2004-07-05 Astrazeneca Ab Novel compounds
SE0401763D0 (sv) * 2004-07-05 2004-07-05 Astrazeneca Ab Compounds
SE0403086D0 (sv) * 2004-12-17 2004-12-17 Astrazeneca Ab Compounds
SE0403085D0 (sv) * 2004-12-17 2004-12-17 Astrazeneca Ab Novel componds
TW200800954A (en) 2006-03-16 2008-01-01 Astrazeneca Ab Novel crystal modifications
TW200740769A (en) * 2006-03-16 2007-11-01 Astrazeneca Ab Novel process
TW200831488A (en) * 2006-11-29 2008-08-01 Astrazeneca Ab Novel compounds

Also Published As

Publication number Publication date
ZA200306737B (en) 2004-11-29
RU2003127734A (ru) 2005-03-20
CA2440630A1 (en) 2002-09-26
NO20034042D0 (no) 2003-09-12
WO2002074748A8 (en) 2004-04-22
ES2352246T3 (es) 2011-02-16
SK287766B6 (sk) 2011-09-05
PL205315B1 (pl) 2010-04-30
EE05431B1 (et) 2011-06-15
RU2285695C2 (ru) 2006-10-20
US7666892B2 (en) 2010-02-23
MY136141A (en) 2008-08-29
JP5140058B2 (ja) 2013-02-06
KR20080071210A (ko) 2008-08-01
WO2002074751A1 (en) 2002-09-26
CN101602731A (zh) 2009-12-16
MY136789A (en) 2008-11-28
UA77408C2 (en) 2006-12-15
US8153673B2 (en) 2012-04-10
JP2004523583A (ja) 2004-08-05
CN1304377C (zh) 2007-03-14
HK1059932A1 (en) 2004-07-23
DE60237965D1 (en) 2010-11-25
MXPA03008181A (es) 2003-12-12
PL364707A1 (en) 2004-12-13
NO20034044D0 (no) 2003-09-12
HUP0400202A3 (en) 2004-10-28
EP1370556A1 (en) 2003-12-17
ES2357138T3 (es) 2011-04-19
PL365099A1 (en) 2004-12-27
US20080306065A1 (en) 2008-12-11
US20040106659A1 (en) 2004-06-03
NZ528140A (en) 2005-02-25
KR100886315B1 (ko) 2009-03-04
IL157652A0 (en) 2004-03-28
JP4390457B2 (ja) 2009-12-24
CN1509286A (zh) 2004-06-30
IS6946A (is) 2003-09-10
IS6943A (is) 2003-09-09
JP2004527515A (ja) 2004-09-09
CA2440631A1 (en) 2002-09-26
IL157656A (en) 2010-11-30
IL157656A0 (en) 2004-03-28
CY1107525T1 (el) 2013-03-13
DE60213216T2 (de) 2007-07-12
RU2003127733A (ru) 2005-03-20
CA2440473A1 (en) 2002-09-26
IS6942A (is) 2003-09-09
CA2440473C (en) 2011-08-30
ATE484496T1 (de) 2010-10-15
US20100273849A1 (en) 2010-10-28
PL364706A1 (en) 2004-12-13
CZ20032500A3 (cs) 2004-02-18
US7368465B2 (en) 2008-05-06
EP1370537A1 (en) 2003-12-17
BR0207983A (pt) 2004-06-15
NO326087B1 (no) 2008-09-15
RU2003127735A (ru) 2005-03-20
EP1370537B1 (en) 2010-10-13
BR0208104A (pt) 2004-03-02
RU2288228C2 (ru) 2006-11-27
CN1962641B (zh) 2012-07-04
ZA200306734B (en) 2004-11-29
NO20034045D0 (no) 2003-09-12
ZA200306732B (en) 2004-11-29
BR0207984A (pt) 2004-06-15
HUP0400327A3 (en) 2005-06-28
EE200300445A (et) 2003-12-15
MXPA03008191A (es) 2004-01-29
DE60213216D1 (en) 2006-08-31
AR035695A1 (es) 2004-06-23
NO20034045L (no) 2003-11-10
EE05364B1 (et) 2010-12-15
NO20034042L (no) 2003-11-10
SK10952003A3 (sk) 2004-05-04
DE60238794D1 (de) 2011-02-10
JP2010077137A (ja) 2010-04-08
EP1370556B1 (en) 2006-07-19
CN1509276A (zh) 2004-06-30
US20080262045A1 (en) 2008-10-23
WO2002074767A8 (en) 2004-04-22
US7754750B2 (en) 2010-07-13
HK1060121A1 (en) 2004-07-30
EP1676846B1 (en) 2010-12-29
SI1370556T1 (sl) 2006-10-31
SK10922003A3 (sk) 2004-05-04
CA2440630C (en) 2011-09-27
MXPA03008177A (es) 2003-12-12
EP1676846A3 (en) 2006-07-26
AU2002237632B2 (en) 2007-05-10
US7625934B2 (en) 2009-12-01
SK287834B6 (sk) 2011-12-05
NZ528106A (en) 2005-03-24
JP2004523581A (ja) 2004-08-05
CZ20032499A3 (cs) 2004-03-17
CN1509272A (zh) 2004-06-30
RU2293729C2 (ru) 2007-02-20
PT1370556E (pt) 2006-11-30
KR20030082987A (ko) 2003-10-23
US7427631B2 (en) 2008-09-23
CZ20032497A3 (cs) 2004-02-18
EP1370534A1 (en) 2003-12-17
CN1962641A (zh) 2007-05-16
CN1269804C (zh) 2006-08-16
UA78502C2 (en) 2007-04-10
US20080171882A1 (en) 2008-07-17
KR20030082989A (ko) 2003-10-23
NO327114B1 (no) 2009-04-27
NZ528107A (en) 2005-06-24
AR035443A1 (es) 2004-05-26
IL157657A0 (en) 2004-03-28
HUP0400194A3 (en) 2004-10-28
NO20034044L (no) 2003-11-10
US20040127528A1 (en) 2004-07-01
IL157652A (en) 2010-11-30
CN100526307C (zh) 2009-08-12
SK10962003A3 (sk) 2004-03-02
ATE493406T1 (de) 2011-01-15
HUP0400194A2 (hu) 2004-07-28
US20110003853A1 (en) 2011-01-06
WO2002074767A1 (en) 2002-09-26
ATE333454T1 (de) 2006-08-15
AU2002237626B2 (en) 2007-05-17
WO2002074748A1 (en) 2002-09-26
DK1370556T3 (da) 2006-10-30
KR20030082986A (ko) 2003-10-23
HUP0400327A2 (hu) 2005-01-28
HK1091492A1 (en) 2007-01-19
EE200300451A (et) 2003-12-15
HUP0400202A2 (hu) 2004-08-30
ZA200306731B (en) 2004-11-29
KR100879905B1 (ko) 2009-01-21
ES2267986T3 (es) 2007-03-16
EE200300449A (et) 2003-12-15
US20040138276A1 (en) 2004-07-15
EP1676846A2 (en) 2006-07-05
UA77667C2 (en) 2007-01-15

Similar Documents

Publication Publication Date Title
SE0100902D0 (sv) Compounds
ATE227264T1 (de) Metalloproteinase-inhibitoren
SE0100903D0 (sv) Compounds
IL159418A0 (en) Novel compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents
DK1385514T3 (da) Spiroinden- og spiroindanforbindelser
DE60230266D1 (de) Phenylpyridincarbonyl piperazinderivate
DE69803907D1 (de) Fungizide 2-Methoxybenzophenone
FI903331A0 (fi) Substituerade kinazolinoner, vilka aer anvaendbara som angiotensin-ii-antagonister.
NO20041493L (no) Kjemiske forbindelser.
BR0209149A (pt) Ftalazinonas
SE0103710D0 (sv) Compounds
FI902555A0 (fi) Diarylstyrylkinolindisyror.
DK1385518T3 (da) Benzimidazolon-forbindelser
MY128164A (en) Compounds
DE60015390D1 (de) Antidiabetische thiazolidindione und ihre herstellung
DE69121259D1 (de) Beta-Lactam-Verbindungen und ihre Herstellung
DE60202669D1 (de) 6-phenylbenzonaphthyidine
BRPI0416678A (pt) pirazolpirimidinas
EA200801365A1 (ru) Замещенные 5-фенил-3,6-дигидро-2-оксо-6h-1,3,4-тиадиазины
NO20023951L (no) Arylpiperaziner og arylpiperidiner og deres anvendelse som metalloproteinaseinhiberende midler
ATE422531T1 (de) Organische verbindungen
BR9902096A (pt) Pitazóis.
DE60039695D1 (de) Antifucoidan antikörper
BR0211620A (pt) Imidazopiridinas substituìdas por alquila para o tratamento de distúrbios gastrointestinais